Atrial fibrillation is the most common clinical arrhythmia. The newest guidelines have significant changes in diagnosis, assessment, and treatment. Join host, Geoff Wall, with guest Matt Boyd, as they evaluate the pharmacotherapy changes in the new guidelines in this two-part episode.

The GameChanger
Rate and rhythm control medications largely have the same clinical outcomes. Patients with heart failure with reduced ejection fraction should try rhythm control first. Monitoring is key for atrial fibrillation pharmacotherapy.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
Mathew Boyd, PharmD
Clinical Pharmacist
Unity Point

Reference
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023 Nov 23:S0735-1097(23)06465-3. doi: 10.1016/j.jacc.2023.08.017. Epub ahead of print. PMID: 38043043.

https://www.jacc.org/doi/10.1016/j.jacc.2023.08.017

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss rate versus rhythm control in patients with atrial fibrillation
2. Develop a monitoring plan and selection of medications in rhythm control

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-030-H01-P
Initial release date: 1/5/2024
Expiration date: 1/5/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram